Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.

about

Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.

Item

http://www.wikidata.org/entity/Q50859000

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Macular cystic changes as pred ...... branch retinal vein occlusion.

@en

Macular cystic changes as pred ...... branch retinal vein occlusion.

@nl

type

Item

label

Macular cystic changes as pred ...... branch retinal vein occlusion.

@en

Macular cystic changes as pred ...... branch retinal vein occlusion.

@nl

prefLabel

Macular cystic changes as pred ...... branch retinal vein occlusion.

@en

Macular cystic changes as pred ...... branch retinal vein occlusion.

@nl

P1476

Macular cystic changes as pred ...... branch retinal vein occlusion.

@en

P2093

Eric Tilgner

http://www.w3.org/2001/XMLSchema#string

Maiara Dalcegio Favretto

http://www.w3.org/2001/XMLSchema#string

Maria Tuisl

http://www.w3.org/2001/XMLSchema#string

Matus Rehak

http://www.w3.org/2001/XMLSchema#string

Peter Wiedemann

http://www.w3.org/2001/XMLSchema#string

P2860

The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia

Retinal gene expression and Müller cell responses after branch retinal vein occlusion in the rat.

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

The burden of disease of retinal vein occlusion: review of the literature.

Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion.

Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion.

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.

Müller cells in the healthy and diseased retina.

Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion.

P304

e592-e596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AOS.13396

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28266152

http://www.w3.org/2001/XMLSchema#string